Acute Bacterial Skin and Skin Structure Infections (ABSSSI ) Market Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

 

Acute Bacterial Skin and Skin Structure Infections Market
Acute Bacterial Skin and Skin Structure Infections (ABSSSI ) Market

Acute bacterial skin and skin structure infections (ABSSSI) are a group of infections caused by bacteria that affect the skin and surrounding tissues. These infections can be caused by a variety of bacteria, including Staphylococcus aureus and Streptococcus pyogenes, and can range in severity from mild to life-threatening. ABSSSI can present as cellulitis, erysipelas, or infected wounds.

The market for ABSSSI treatments has been growing rapidly in recent years, driven by an increase in the prevalence of antibiotic-resistant bacteria and the development of new and effective treatments for these infections.

Market Overview

The Acute Bacterial Skin and Skin Structure Infections Market was valued at approximately $5.4 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 5.8% from 2021 to 2028. The market is driven by factors such as the increasing prevalence of ABSSSI, rising healthcare expenditure, and the development of new and effective treatments.

The Acute Bacterial Skin and Skin Structure Infections Market is segmented by treatment type, including antibiotics, immunoglobulins, and others. Antibiotics are the most commonly used treatment for ABSSSI, and this segment accounted for the largest market share in 2020. Within the antibiotics segment, the cephalosporin class of antibiotics is the most commonly prescribed.

Geographically, North America dominates the Acute Bacterial Skin and Skin Structure Infections Market, followed by Europe and the Asia Pacific. The high prevalence of ABSSSI in North America, along with the presence of major market players in the region, is driving the growth of the market in this region.

Key Market Players

The Acute Bacterial Skin and Skin Structure Infections Market is highly competitive, with several major players vying for market share. Some of the key market players include:

Merck & Co., Inc. - Merck & Co., Inc. is a global pharmaceutical company that develops and markets drugs for a wide range of diseases, including ABSSSI. The company's flagship product for ABSSSI is Zerbaxa, a combination antibiotic that has been approved for the treatment of complicated intra-abdominal infections and ABSSSI.

Pfizer Inc. - Pfizer Inc. is a global pharmaceutical company that develops and markets drugs for a wide range of diseases, including ABSSSI. The company's flagship product for ABSSSI is Dalvance, a second-generation lipoglycopeptide antibiotic that has been approved for the treatment of ABSSSI.

Tags: healthcare, Healthcare Industry, Pharmaceutical, Acute Bacterial Skin and Skin Structure Infections, Acute Bacterial Skin and Skin Structure Infections Market

Comments

Popular posts from this blog

The Role of the Foodservice Industry in Driving the French Fries Market

Market Share and Revenue Analysis of the Microdermabrasion Devices Market

The Growing Demand for Healthcare Staffing Market: Trends and Opportunities